TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Conditions

• Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 99 Years

Healthy Volunteers

Not accepted

Study Details

This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.

Key Dates

Start date

Jun 26, 2024

Status verified

Feb 2026

Primary completion

Jun 1, 2029

Completion

Jun 1, 2029

Study Design

Enrollment

500 participants (estimated)

Arms

• Arm: Cohort 001: KRAS mutated CRC
  No intervention.
• Arm: Cohort 002: KRAS mutated PDAC
  No intervention.
• Arm: Cohort 003: KRAS mutated NSCLC
  No intervention.
• Arm: Cohort 004: Gastric 1L Plus
  No intervention.
• Arm: Cohort 005: mCRPC 1L Plus
  No intervention.
• Arm: Cohort 006: Pan Tumor ADCs
  No intervention.
• Arm: Cohort 007: Stage III-IV EGFR Activating Mutation NSCLC
  No intervention.

Primary Outcome Measure

Changes in ctDNA from baseline, on-treatment and post-treatment blood samples. [ Time Frame: 5 years ]

Central Contacts

• Lauren Lopez
  8007394137
  [email protected]

Locations (31)

Find similar trials in Birmingham, AL

Related Studies

• Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Collection of Blood and Urine From Patients Undergoing Radiation Therapy
  Enrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
• Effects of Oncological Treatment During Pregnancy on Mother and Child
  Recruiting · University Hospital, Gasthuisberg · Camden, New Jersey
• Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
  Recruiting · Lahey Clinic · Burlington, Massachusetts